Skip to main content

Table 4 Treatment Outcome of individual patients

From: Radiofrequency ablation for liver metastases in patients with gastric cancer as an alternative to hepatic resection

Clinical data Liver metastasis RFA Recur
Case Comorbidity PS No Lobar Chronicity Size (cm) CTx after RFA Number of initial RFA Recur Pattern Tx after recur OS (mon) DFS (mon) Survivala
1 No 0 1 Uni Meta 2.6 Yes 2 Yes Liver RFA 69.1 10.3 Death
2 Yes 1 1 Uni Meta 3.7 Yes 1 Yes Liver CTx 20.7 0.8 Death
3 No 0 5 Bi Meta 1 No 2 Yes Liver None 40.5 11.4 Death
4 No 1 2 Uni Syn 2 Yes 1 No    79.6 42.3 Alive
5 Yes 1 1 Uni Meta 1.7 No 1 Yes Liver RFA 21.8 4.7 Death
6 No 0 1 Uni Meta 3.3 Yes 1 No    22.9 22.6 Alive
7 Yes 1 1 Uni Meta 0.5 No 1 Yes Virchow Node CTx 12.8 9.4 Alive
8 Yes 0 1 Uni Meta 1.5 No 1 Yes Lung None 25.1 8.9 Alive
9 Yes 2 1 Uni Meta 4.2 No 1 Yes Liver None 20.0 7.9 Alive
10 Yes 1 1 Uni Meta 3.7 No 1 No    3.6 3.3 Alive
11 No 2 2 Uni Meta 3.2 NO 1 No    15.3 14.4 Alive
  1. PS, Performance status based on Eastern Cooperative Oncology Group, No number of metastatic lesion; Lobar, lobar distributaion; Uni, unilobar; Bi, bilobar; Meta, metachronous; Syn synchronous, CTx chemotherapy, Recur recurrence, Tx treatment, OS overall survival, DFS disease free survival, mon months
  2. aSurvival at the time of analysis